Drug Profile
Research programme: RNAi-based influenza therapeutics - Alnylam/Arrowhead Pharmaceuticals
Alternative Names: ALN-FLU01; Pandemic influenza therapy - Alnylam/Arrowhead; Short-interfering RNA-based influenza therapies - Alnylam/ArrowheadLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Novartis; University of Georgia
- Developer Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype; Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in Europe (Parenteral)